Analyst Report: DD

1. EXECUTIVE SUMMARY

DuPont rose 8.61% to $153.46 on Tuesday 3 November 2026 after it reported third-quarter results before the open and raised full-year guidance for the third quarter running. Adjusted EPS of $2.09 compared with a consensus of about $1.87 to $1.88, and full-year adjusted EPS guidance moved to $7.47–$7.52 from $7.17–$7.32, against a consensus of about $7.25 (Benzinga, GuruFocus, Seeking Alpha). Volume of 2,887,800 shares was 2.87 times the 50-session average. Peers MMM (-0.73%) and HON (+0.13%) moved little and the S&P 500 gained 0.36%, so the rise belongs to the company. The stock now sits 1.65% below its 52-week high of $156.04. Management cited an order book "solidly up double digits" and margin gains, while delayed Middle East water projects remain a drag that guidance already assumes. No analyst target changes dated inside the window turned up, so the reaction so far is a price move without a revision cycle behind it.

2. THE CATALYST

DuPont published Q3 2026 results before the open on 3 November, and management said it beat its own Q3 guidance (DuPont press release via PRNewswire/TradingView).

Sources disagree on revenue. Chartmill cites a $1.898bn consensus and calls revenue in line, while Benzinga and GuruFocus describe a beat against about $1.84bn. The EPS beat is clear under either consensus figure.

Management said the beat came from over 2% net productivity and about 90 bps of margin expansion, and described the order book as "solidly up double digits" year over year (Benzinga, Investing.com). Morningstar's analyst said DuPont passed cost inflation through to customers while still expanding margins (Investing.com). Q3 buybacks totalled about $350m, including a $250m accelerated repurchase, and another $250m is planned for Q4 (GuruFocus, Seeking Alpha).

On timing, Seeking Alpha reported a premarket gain of about 3.3%, and Investing.com had the stock up about 8.5% in the afternoon. The session opened at $149.95 against a prior close of $141.30 and closed at $153.46, so most of the move came in regular trading. The prior session, 2 November, closed up 0.89% on volume of 1,654,200, and the research found no story for it.

3. COMPANY PROFILE

DuPont de Nemours is a specialty chemicals company in the Basic Materials sector with a market cap of $20.72bn. It operates through two segments, Healthcare & Water Technologies and Diversified Industrials. Products include Tyvek for medical devices, packaging and protective suits, and water filtration and separation systems for industrial wastewater, energy, municipal and desalination uses. The facts panel lists MMM and HON as industrial conglomerate peers. An 8-K exhibit to the Q2 release says the company's GICS classification moved to Industrials effective 31 July 2026 (the date was partly truncated in the source).

DuPont raised guidance in the Q1 release (5 May 2026), the Q2 release and now Q3 (SEC 8-K exhibits; Benzinga). Management said AI tools are shortening development cycles (Benzinga). CNBC Investing Club noted that the biopharma water end market is performing well and that DuPont launched a purification product for peptide manufacturing in October.

4. DEEP DIVE ANALYSIS

Do fundamentals justify the move? The EPS beat was roughly 12% against consensus, and the full-year guidance midpoint of $7.495 sits about 3.4% above the $7.25 consensus. Guidance rose after a pattern of earlier raises, which gives the latest increase more weight as evidence of an improving run rate. At $153.46 the forward P/E is 19.2 and the trailing P/E is 41.3. Inference: the large gap between the two multiples points to earnings that are rising quickly relative to the trailing base, which is consistent with the strong guidance.

Peers and sector. MMM and HON barely moved, and Investing.com described the rise as entirely company-specific against a muted index. The Motley Fool framed the beat against a prolonged global slump in chemicals. The research found no sector story explaining the move. A Celanese Q3 call summary appeared on 3 November, but it was not reviewed.

Comparable episodes. The research could not find the price reactions to the Q1 or Q2 releases, so the size of this move cannot be ranked against prior ones. After the 10 February 2026 Q4 results, BMO raised its target on 12 February (MarketBeat). The 52-week high of $156.04 was set on 12 February, two sessions after that release.

Bull case.

• A double-digit order book increase, margin expansion and a third consecutive guidance raise.
• Buybacks of about $350m in Q3 and a planned $250m in Q4.
• Q4 EPS guidance of $1.90–$1.95 is above the $1.88 estimate the site shows for Q3, which keeps earnings momentum intact.
• The 18-analyst average target of $165.29 (stockanalysis.com, snapshot taken when the price was $140.05) sits 7.7% above the close.

Bear case.

• Large Middle East water project orders are delayed, and guidance assumes the disruption continues.
• The stock gained 15.14% over 20 sessions, so much of the good news now sits in the price.
• Targets are mixed. RBC cut to $160 from $176 (15 October), Bank of America holds at $159 (19 October), Barclays initiated at $156 (12 October), and JPMorgan downgraded to Neutral at $145 (undated). Several of these sit close to or below the new price. CNBC Investing Club kept a Hold rating on 3 November and said it took profits on the rise.
• Wells Fargo ($166, 16 October) and Citi ($162, 16 October) kept Buy ratings with targets above the close.

The research found no target changes dated inside the move window. Kalkine Media's headline mentions an aramids divestiture, a reverse stock split and an electronics spin-off. None of this was confirmed by sources the researcher could read, and it is left out of the analysis.

5. TECHNICAL SNAPSHOT

The close of $153.46 stands 15.8% above the 50-day average of $132.57 and 11.3% above the 200-day average of $137.84, having moved from just above both averages to well above them in a single session. It is the highest close in the displayed table and sits $2.58 under the 52-week high of $156.04 (the session high was $155.61). The nearest support is the prior close of $141.30, and the intraday low of $143.36 marks the level buyers defended during the session. Volume of 2,887,800 was 2.87 times the 50-session average and the highest in the table, and the prior session's 1,654,200 shows positioning ahead of the release.

6. RISK FACTORS

• Delayed Middle East water orders could extend beyond the assumption in guidance.
• A one-session gain of 8.61% leaves room for profit-taking, which CNBC's Investing Club has already done.
• Analyst targets in the research cluster between $145 and $166, and several sit near the current price.
• Revenue consensus figures differ across sources, which makes the sales beat less clear than the EPS beat.
• The chemicals sector remains in what the Motley Fool called a prolonged global slump.
• Upcoming dates: the Q4 2026 results are not yet dated in the sources found. The $250m Q4 buyback is already announced.

7. ACTIONABLE OUTLOOK

Short term (1-2 weeks). The stock trades just under its 52-week high on heavy volume. The $156.04 level is the next test, with $141.30 as the first support. Analyst target revisions following the results would be the main fresh input, and none had been published within the window.

Medium term (1-3 months). The path depends on whether order growth and margin gains hold into Q4, where guidance calls for EPS of $1.90–$1.95. Evidence of Middle East project orders resuming would add to the case, and further delays would weigh on it. Buyback execution provides some support.

Long term. The thesis has improved at the margin: three consecutive guidance raises, margin expansion and a growing order book support it. The delayed water projects and the sector backdrop remain the main constraints. This is analysis only and not personal financial advice.